Families caring for individuals with Duchenne muscular dystrophy (DMD) face significant financial burdens from necessary home ...

Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy ...

Dysfunctional dystrophin, the muscle protein affected in Duchenne, leads to an important choice for patients about how to ...

Taiho-developed TAS-205 is designed to selectively inhibit hematopoietic prostaglandin D synthase (HPGDS), an enzyme related ...

Sarepta Therapeutics Inc. misled investors about the safety and prospects for one of its Duchenne muscular dystrophy ...

Absent a federal committee’s recommendation, Duchenne muscular dystrophy advocates are trying to get states to adopt ...

The FDA found that data from a single Phase II study were “insufficient” to justify an accelerated approval review for ...

Although only living in the Berkshires for a few years, Evan Butts has already ingrained himself into the community. A server ...

New consensus guidelines outline best practices for orthopedic management in Duchenne muscular dystrophy, focusing on ...

In yet another fail for the Duchenne muscular dystrophy (DMD) field, Taiho Pharmaceutical Co. Ltd.’s pizuglanstat (TAS-205) did not meet the primary endpoint in a phase III trial. The phase III ...

In an opinion article, investigators argue that gene therapies may not achieve their full potential if the innate inflammation in Duchenne muscular dystrophy is not effectively managed.

One visit to Virginia Peninsula Community College’s Historic Triangle Campus last summer eased any concerns they might have had. Soon after entering the building, Nicholas and his mother, Liz, were ...